No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: A [H 2 15O]-positron emission tomography study

Journal of Clinical Psychopharmacology

Volumn 21, Issue 1, 2001, Pages 66-71

  Gamma, Alex ^a   Buck, Alfred ^b   Berthold, Thomas ^b   Vollenweider, Franz X ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; ATTENTION; BRAIN BLOOD FLOW; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; ELECTROENCEPHALOGRAM; FEMALE; HAMILTON SCALE; HUMAN; MALE; MOOD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TASK PERFORMANCE;

ADULT; AFFECT; AGE FACTORS; AROUSAL; BRAIN; COGNITION; DEPRESSION; FEMALE; HALLUCINOGENS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXYGEN RADIOISOTOPES; PATIENT EDUCATION; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035143551     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200102000-00012     Document Type: Article

References (32)

1. MDMA ("Ecstasy") abuse: Psychopathological features and craving for chocolate: A case series
2. MDMA (Ecstasy) precipitation of panic disorder MDMA (Ecstasy) precipitation of panic disorder
3. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy")
4. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): Week-end 'high' followed by mid-week low
5. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function?
6. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: A controlled study
7. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys
8. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors
9. Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: A presynaptic serotonergic positron emission tomography ligand?
10. (±)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates
11. The role of serotonin in panic, anxiety and depression
12. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings
13. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans - Methodological considerations and preliminary observations
14. 15O]-PET in healthy humans
15. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers
16. 2O PET study in humans
17. No effect of depression on [15O]H2O PET response to intravenous d-fenfluramine
18. Fluoxetine effects on cerebral glucose metabolism
19. SPECT and PET imaging in mood disorders
20. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, I. Regional cerebral blood flow (rCBF) evidence
21. The continuous performance test revisited with neuroelectric brain mapping: Impaired orienting in children with attention deficits
22. Spatial registration and normalization of images
23. Impaired attention, genetics, and the pathophysiology of schizophrenia
24. Cognitive performance in recreational users of MDMA or "ecstasy": Evidence for memory deficits
25. Memory deficits associated with recreational use of "ecstasy" (MDMA)
26. Memory impairment in abstinent MDMA ("Ecstasy") users
27. Serotonergic function after (±)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans
28. MDMA ("ecstasy") consumption in the context of polydrug abuse: A report on 150 patients
29. Recreational use of "Ecstasy" (MDMA) is associated with elevated impulsivity